Palbociclib and trastuzumab in HER2+ metastatic breast cancer
Final overall survival data from SOLTI-1303-PATRICIA trial highlight the relevance of gene expression profiling in HER2+ breast cancer, validating the potential of non-chemotherapy approaches in selected patients